Phaseline

Targets › LAIR2

LAIR2 (Leukocyte-associated immunoglobulin-like receptor 2): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Oncology; next expected readout Dec 2028.

Open in Phaseline: the race on LAIR2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNC410
LAIR-2 fusion protein
LAIR2Phase 2Pancreatic CancerDec 2028

Conditions

Pancreatic Cancer (1)

Modalities

mixed (1)

Companies

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.